US Patent

US12551483 — Formulations of vimseltinib

Formulation · Assigned to Deciphera Pharmaceuticals LLC · Expires 2044-12-06 · 19y remaining

Vulnerability score 55/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects formulations of vimseltinib, a compound represented by Formula (I), and methods of preparing and using these formulations.

USPTO Abstract

Described herein, in part, are pharmaceutically acceptable formulations comprising a compound represented by Formula (I) and methods of preparing and using the formulations:

Drugs covered by this patent

Patent Metadata

Patent number
US12551483
Jurisdiction
US
Classification
Formulation
Expires
2044-12-06
Drug substance claim
No
Drug product claim
Yes
Assignee
Deciphera Pharmaceuticals LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.